Core Insights - The company reported a revenue of 244 million yuan for the first half of 2025, representing a year-on-year decline of 10.5% due to internal business restructuring and industry environment impacts [1] - The company's loss decreased by 83.3% to 29.31 million yuan, with adjusted net loss (non-IFRS) at 28.70 million yuan, indicating an improvement in profit structure [1] - The core business, particularly SaaS product revenue, saw growth, increasing its share to 33.8%, while digital service revenue declined but maintained a gross margin of 41% [1] Financial Performance - The company effectively controlled expenses, with sales and administrative expenses decreasing by 26.6% and 73.4% year-on-year, respectively, contributing to improved operational efficiency [1] - As of June 30, the company held cash and cash equivalents, short-term deposits, and government bond investments totaling 1.149 billion yuan, with a current ratio of 5.66, indicating robust cash flow [1] Strategic Developments - The company has launched a "digital employee" system, embedding intelligent agents into its core platform, and is transitioning clients from "tool procurement" to "value sharing" through a dual-dimensional billing model [2] - Research and development investment accounted for over 15% of total expenditure in the first half of the year, with compliance delivery centers in China, the US, and other regions now operational [2] - The company experienced growth in overseas revenue, driven by the acceleration of Chinese innovative pharmaceutical companies entering international markets and increased demand for execution efficiency and compliance from international clients [2] Long-term Outlook - Overall, the company is optimizing its business structure and implementing an AIaaS strategy to improve profit quality, maintain stable cash flow, and accelerate overseas business expansion, laying a foundation for medium to long-term growth [2]
太美医疗科技中期业绩公布：AI战略推动亏损大幅度收窄，赢利预期加速，海外收入持续增长